404 related articles for article (PubMed ID: 16492146)
1. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism.
Porat Y; Abramowitz A; Gazit E
Chem Biol Drug Des; 2006 Jan; 67(1):27-37. PubMed ID: 16492146
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions.
Porat Y; Mazor Y; Efrat S; Gazit E
Biochemistry; 2004 Nov; 43(45):14454-62. PubMed ID: 15533050
[TBL] [Abstract][Full Text] [Related]
3. (-)-epigallocatechin-3-gallate (EGCG) maintains kappa-casein in its pre-fibrillar state without redirecting its aggregation pathway.
Hudson SA; Ecroyd H; Dehle FC; Musgrave IF; Carver JA
J Mol Biol; 2009 Sep; 392(3):689-700. PubMed ID: 19616561
[TBL] [Abstract][Full Text] [Related]
4. Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid beta protein.
Akaishi T; Morimoto T; Shibao M; Watanabe S; Sakai-Kato K; Utsunomiya-Tate N; Abe K
Neurosci Lett; 2008 Oct; 444(3):280-5. PubMed ID: 18761054
[TBL] [Abstract][Full Text] [Related]
5. The molecular mechanisms of the anti-amyloid effects of phenols.
Shoval H; Lichtenberg D; Gazit E
Amyloid; 2007 Mar; 14(1):73-87. PubMed ID: 17453627
[TBL] [Abstract][Full Text] [Related]
6. New polyphenols active on beta-amyloid aggregation.
Rivière C; Richard T; Vitrac X; Mérillon JM; Valls J; Monti JP
Bioorg Med Chem Lett; 2008 Jan; 18(2):828-31. PubMed ID: 18042380
[TBL] [Abstract][Full Text] [Related]
7. Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation.
Carver JA; Duggan PJ; Ecroyd H; Liu Y; Meyer AG; Tranberg CE
Bioorg Med Chem; 2010 Jan; 18(1):222-8. PubMed ID: 19931462
[TBL] [Abstract][Full Text] [Related]
8. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation.
Takahashi T; Mihara H
Acc Chem Res; 2008 Oct; 41(10):1309-18. PubMed ID: 18937396
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the mysteries of protein folding and misfolding.
Ecroyd H; Carver JA
IUBMB Life; 2008 Dec; 60(12):769-74. PubMed ID: 18767168
[TBL] [Abstract][Full Text] [Related]
10. Phenolsulfonphthalein, but not phenolphthalein, inhibits amyloid fibril formation: implications for the modulation of amyloid self-assembly.
Levy M; Porat Y; Bacharach E; Shalev DE; Gazit E
Biochemistry; 2008 Jun; 47(22):5896-904. PubMed ID: 18457421
[TBL] [Abstract][Full Text] [Related]
11. Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action.
Bartolini M; Bertucci C; Bolognesi ML; Cavalli A; Melchiorre C; Andrisano V
Chembiochem; 2007 Nov; 8(17):2152-61. PubMed ID: 17939148
[TBL] [Abstract][Full Text] [Related]
12. Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid.
Kim H; Park BS; Lee KG; Choi CY; Jang SS; Kim YH; Lee SE
J Agric Food Chem; 2005 Nov; 53(22):8537-41. PubMed ID: 16248550
[TBL] [Abstract][Full Text] [Related]
13. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease.
Glabe CG
Neurobiol Aging; 2006 Apr; 27(4):570-5. PubMed ID: 16481071
[TBL] [Abstract][Full Text] [Related]
14. Influence of dendrimer's structure on its activity against amyloid fibril formation.
Klajnert B; Cortijo-Arellano M; Cladera J; Bryszewska M
Biochem Biophys Res Commun; 2006 Jun; 345(1):21-8. PubMed ID: 16674918
[TBL] [Abstract][Full Text] [Related]
15. The anti-amyloidogenic effect is exerted against Alzheimer's beta-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure.
Hirohata M; Hasegawa K; Tsutsumi-Yasuhara S; Ohhashi Y; Ookoshi T; Ono K; Yamada M; Naiki H
Biochemistry; 2007 Feb; 46(7):1888-99. PubMed ID: 17253770
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro.
Rivière C; Richard T; Quentin L; Krisa S; Mérillon JM; Monti JP
Bioorg Med Chem; 2007 Jan; 15(2):1160-7. PubMed ID: 17049256
[TBL] [Abstract][Full Text] [Related]
17. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.
Ferreira ST; Vieira MN; De Felice FG
IUBMB Life; 2007; 59(4-5):332-45. PubMed ID: 17505973
[TBL] [Abstract][Full Text] [Related]
18. The generic amyloid formation inhibition effect of a designed small aromatic β-breaking peptide.
Frydman-Marom A; Shaltiel-Karyo R; Moshe S; Gazit E
Amyloid; 2011 Sep; 18(3):119-27. PubMed ID: 21651439
[TBL] [Abstract][Full Text] [Related]
19. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility.
Reinke AA; Gestwicki JE
Chem Biol Drug Des; 2007 Sep; 70(3):206-15. PubMed ID: 17718715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
